- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
More ▼
Key statistics
On Monday, Atara Biotherapeutics Inc (ATRA:NSQ) closed at 0.5781, 191.09% above the 52 week low of 0.1986 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.5573 |
---|---|
High | 0.600 |
Low | 0.55 |
Bid | 0.55 |
Offer | 0.600 |
Previous close | 0.5609 |
Average volume | 1.18m |
---|---|
Shares outstanding | 120.42m |
Free float | 109.22m |
P/E (TTM) | -- |
Market cap | 67.54m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 21:00 BST.
More ▼